Executive Order 14221: Making America Healthy Again by Empowering Patients With Clear, Accurate, and Actionable Healthcare Pricing Information

What does Executive Order 14221 do?

Treasury, Labor and HHS had to prepare a price-transparency framework; CMS implementation required separate rules or guidance.

Reading the operative provisions of Executive Order 14221

The order is aimed at making health-care prices more useful before a patient receives care. It directs Treasury, Labor and HHS to build on existing transparency rules and pursue information that reflects actual prices, including negotiated rates, rather than relying only on list prices. It also calls for better public access and stronger enforcement. The order assigns work to agencies; it does not itself set a universal price for a procedure or require every provider to accept the same payment. Its operative text is the Federal Register publication of EO 14221.

The three departments have different roles in the price-transparency system. HHS oversees rules for hospitals and other covered providers, Labor administers disclosure duties for group health plans, and Treasury has related tax and employer-plan responsibilities. A cross-agency directive can ask them to align definitions, improve the usability of disclosures and enforce existing requirements, but any new binding obligation must come through the relevant statutory and regulatory authority. For patients, usable information means more than a large file: the service, provider, plan, negotiated amount and date must be clear enough to compare. The order’s goal is to move disclosures toward that practical use.

It is important to distinguish a posted price from a guaranteed out-of-pocket cost. A patient’s final bill can depend on network status, deductible, coinsurance, billing codes, complications and the services actually provided. Transparency can help a patient ask better questions or compare routine services, but it cannot by itself resolve medical necessity or surprise billing disputes. The order also does not change the clinical relationship between patient and provider. Its success should be evaluated by later agency rules, data completeness, enforcement actions and whether consumers can find comparable prices—not by the existence of a federal directive alone.